硫化氢对低氧性肺动脉高压大鼠FDX1-铜死亡途径的干预
王淑远 , 黄曼 , 陈思安 , 韩丛美 , 程缘 , 袁琳波 , 叶环 , 王万铁
中国临床药理学与治疗学 ›› 2026, Vol. 31 ›› Issue (7) : 875 -884.
硫化氢对低氧性肺动脉高压大鼠FDX1-铜死亡途径的干预
Intervention of hydrogen sulfide on FDX1-cuproptosis pathway in rats with hypoxemic pulmonary hypertension
目的: 探究硫化氢 (hydrogen sulfide, H2S)是否通过铁氧化还原蛋白 1(ferredoxin 1, FDX1)-铜死亡途径来改善大鼠低氧性肺动脉高压(hypoxic pulmonary hypertension,HPH)。方法: 雄性 Sprague Dawley(SD)大鼠随机分为 Control 组、Hypoxia 组和 Hypoxia+NaHS 组,每组各 10 只。Control 组大鼠置于常氧(21% O2)环境中,每天腹腔注射等体积生理盐水;Hypoxia 组大鼠和 Hypoxia+NaHS 组大鼠置于低氧箱中,每天腹腔注射 14 μmol/kg 的 NaHS。造模 21 d 结束后,用右心导管法检测各组大鼠的平均肺动脉压(mPAP), 称重并计算右心室肥厚指数 (RVHI);ELISA 法检测内皮素-1(ET-1)、一氧化氮(NO)和前列环素(PGI2)的含量;电感耦合等离子体质谱(ICP-MS)法检测铜离子浓度; Western blot 法检测铜转运蛋白 1(CTR1)、 铜转运 ATP 酶 α(ATP7A)、 铜转运 ATP 酶 β(ATP7B)、FDX1、硫辛酸合成酶(LIAS)、二氢硫辛酸转乙酰基酶(DLAT)、二氢硫辛酸转乙酰基酶二聚体(DLAT Dimer)、二氢硫辛酰胺 S-琥珀酰转移酶 (DLST); RT-qPCR 法检测 FDX1、 LIAS、 DLAT、 二氢硫辛酰胺脱氢酶 (DLD)mRNA 表达水平;JC-1 试剂盒检测线粒体膜电位变化;化学发光法检测 ATP 含量;ELISA 法检测丙酮酸脱氢酶 E1 亚基 α1(PDHA1)含量;磺基水杨酸法检测柠檬酸 (CA)含量。结果: 与 Control 组比较,Hypoxia 组中 mPAP 和 RVHI 显著上升;ET-1 的浓度显著升高而 NO 和 PGI2 的浓度显著降低;铜离子浓度显著升高;铜转运蛋白 1 表达含量显著升高,铜外排蛋白 ATP7A、ATP7B 表达含量显著降低;铜死亡相关蛋白 FDX1、LIAS、DLAT、DLST 表达含量均显著降低而 DLAT 二聚体蛋白表达含量显著升高;FDX1、LIAS、DLAT、DLD 基因 mRNA 表达水平显著降低;线粒体功能指标 JC-1 和 ATP 表达水平显著降低 ; 三羧酸循环指标 PDHA1 和 CA 表达含量显著降低(均 P<0.05)。与 Hypoxia 组比较,Hypoxia+NaHS 组中的上述指标的变化均可被治疗药物 NaHS 显著逆转。结论: H2S 可能通过调控 FDX1-铜死亡途径影响肺组织细胞线粒体功能、代谢,从而缓解肺血管收缩,改善肺动脉高压。
AIM: To investigate whether hydrogen sulfide (H2S) improves hypoxic pulmonary hypertension (HPH) in rats through the FDX1-cuproptosis pathway. METHODS: Male Sprague-Dawley (SD) rats were randomly assigned to the Control group; Hypoxia group and Hypoxia+NaHS group, with 10 rats in each group. Rats in the Control group were housed in a normoxic environment (21% O2) and received a daily intraperitoneal injection of an equal volume of normal saline; rats in the Hypoxia group and Hypoxia+NaHS group were placed in hypoxic chambers and received a daily intraperitoneal injection of 14 μmol/kg NaHS. After 21 days of model establishment, the mean pulmonary arterial pressure (mPAP) of each group was measured by right heart catheterization and the right ventricular hypertrophy index (RVHI) was calculated after weighing. The levels of endothelin-1 (ET-1), nitric oxide (NO) and prostacyclin (PGI2) were measured by ELISA. Copper ion concentration was detected by inductively coupled plasma mass spectrometry (ICP-MS). The protein levels of copper transporter 1 (CTR1), copper-transporting ATPase α (ATP7A), copper-transporting ATPase β (ATP7B), ferredoxin 1 (FDX1), lipoic acid synthase (LIAS), dihydrolipoamide S-acetyltransferase (DLAT), dihydrolipoamide S-acetyltransferase dimer (DLAT Dimer) and dihydrolipoamide S-succinyltransferase (DLST) were detected by Western blot. The mRNA expression levels of FDX1, LIAS, DLAT and dihydrolipoamide dehydrogenase (DLD) were detected by RT-qPCR. Mitochondrial membrane potential was assessed using the JC-1 kit. ATP content was measured by chemiluminescence. The level of pyruvate dehydrogenase E1 subunit alpha 1 (PDHA1) was measured by ELISA. Citric acid (CA) content was measured by the sulfosalicylic acid method. RESULTS: Compared with the Control group, the Hypoxia group showed significantly increased mPAP and RVHI; significantly elevated ET-1 concentration while NO and PGI2 concentrations were significantly decreased; significantly increased copper ion concentration; significantly elevated expression of copper transporter 1 while the expressions of copper efflux proteins ATP7A and ATP7B were significantly decreased; the expressions of cuproptosis-related proteins FDX1, LIAS, DLAT and DLST were all significantly decreased, whereas the expression of DLAT dimer is significantly increased; the mRNA expression levels of FDX1, LIAS, DLAT and DLD were significantly decreased; the mitochondrial function indicators JC-1 and ATP levels were significantly decreased and the tricarboxylic acid cycle indicators PDHA1 and CA levels were significantly decreased (allP<0.05). Compared with the Hypoxia group, all the above changes in the Hypoxia+NaHS group were significantly reversed by the therapeutic agent NaHS. CONCLUSION: H2S may regulate the FDX1-cuproptosis pathway, thereby affecting mitochondrial function and metabolism in lung tissue cells, alleviating pulmonary vasoconstriction and ameliorating pulmonary hypertension.
| [1] |
李彦霖, 王一川, 吴剑华, |
| [2] |
Nakamura K, Akagi S, Ejiri K, |
| [3] |
|
| [4] |
|
| [5] |
Tsvetkov P, Coy S, Petrova B, |
| [6] |
Cirino G, Szabo C, |
| [7] |
|
| [8] |
|
| [9] |
|
| [10] |
|
| [11] |
|
| [12] |
程缘, 田云娜, 黄曼, |
| [13] |
刘军杰, 黄国雄, 黎静, |
| [14] |
|
| [15] |
罗勤. 中国肺动脉高压诊治临床路径[J].中国循环杂志, 2023, 38(7): 691-703. |
| [16] |
|
| [17] |
|
| [18] |
|
| [19] |
|
| [20] |
朱明强, 谢星, 廖启成, |
| [21] |
|
| [22] |
|
| [23] |
任俏慧, 朱欣悦, 吕伟, |
| [24] |
|
| [25] |
|
| [26] |
|
| [27] |
汪鸣, 赵信科, 刘生发, |
| [28] |
|
浙江省介入肺脏病重点实验室建设项目(2019E10014)
/
| 〈 |
|
〉 |